Literature DB >> 9028325

Chronic lymphocytic leukemia B cells are resistant to the apoptotic effects of transforming growth factor-beta.

R S Douglas1, R J Capocasale, R J Lamb, P C Nowell, J S Moore.   

Abstract

Chronic lymphocytic leukemia (CLL) is the most common leukemia of the western world and is characterized by a slowly progressing accumulation of clonal CD5+ B cells. Our laboratory has investigated the role of transforming growth factor-beta (TGF-beta) and interleukin-4 (IL-4) in the pathogenesis of B-cell expansion in CLL. In vitro addition of TGF-beta did not increase spontaneous apoptosis of B cells from most CLL patients, as determined using the TUNEL method, compared with a twofold increase observed in cultures of normal B cells. There was similar expression of TGF-beta type II receptors on both CLL B cells and normal B cells. In contrast to apoptosis, CLL B-cell proliferation was variably inhibited with addition of TGF-beta. In vitro addition of IL-4, previously reported to promote CLL B-cell survival, dramatically reduced spontaneous apoptosis of CLL B cells compared with normal B cells. CLL B-cell expression of IL-4 receptors was increased compared to normal B cells. Thus, our results show aberrant apoptotic responses of CLL B cells to TGF-beta and IL-4, perhaps contributing to the relative expansion of the neoplastic clone.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9028325

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  22 in total

1.  Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma.

Authors:  Thomas Clozel; ShaoNing Yang; Rebecca L Elstrom; Wayne Tam; Peter Martin; Matthias Kormaksson; Samprit Banerjee; Aparna Vasanthakumar; Biljana Culjkovic; David W Scott; Sarah Wyman; Micheal Leser; Rita Shaknovich; Amy Chadburn; Fabrizio Tabbo; Lucy A Godley; Randy D Gascoyne; Katherine L Borden; Giorgio Inghirami; John P Leonard; Ari Melnick; Leandro Cerchietti
Journal:  Cancer Discov       Date:  2013-08-16       Impact factor: 39.397

2.  Transforming growth factor-beta and multidrug resistance in chronic lymphocytic leukemia.

Authors:  W R Friedenberg; S A Salzman; S M Phan; J K Burmester
Journal:  Med Oncol       Date:  1999-07       Impact factor: 3.064

3.  Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells.

Authors:  U Klein; Y Tu; G A Stolovitzky; M Mattioli; G Cattoretti; H Husson; A Freedman; G Inghirami; L Cro; L Baldini; A Neri; A Califano; R Dalla-Favera
Journal:  J Exp Med       Date:  2001-12-03       Impact factor: 14.307

Review 4.  Aberrant responses of human lymphocytic neoplasms to cytokine regulation.

Authors:  P C Nowell; J S Moore
Journal:  Immunol Res       Date:  1998       Impact factor: 2.829

5.  The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia.

Authors:  Matthew D Blunt; Stefan Koehrer; Rachel C Dobson; Marta Larrayoz; Sarah Wilmore; Alice Hayman; Jack Parnell; Lindsay D Smith; Andrew Davies; Peter W M Johnson; Pamela B Conley; Anjali Pandey; Jonathan C Strefford; Freda K Stevenson; Graham Packham; Francesco Forconi; Greg P Coffey; Jan A Burger; Andrew J Steele
Journal:  Clin Cancer Res       Date:  2016-10-03       Impact factor: 12.531

6.  Association of interleukin-10, tumor necrosis factor-α and transforming growth factor-β gene polymorphisms with the outcome of diffuse large B-cell lymphomas.

Authors:  Olivera Tarabar; Bojana Cikota-Aleksić; Ljiljana Tukić; Nenad Milanović; Aleksandar Aleksić; Zvonko Magić
Journal:  Int J Clin Oncol       Date:  2013-03-27       Impact factor: 3.402

Review 7.  Role of transforming growth factor-beta in hematologic malignancies.

Authors:  Mei Dong; Gerard C Blobe
Journal:  Blood       Date:  2006-02-16       Impact factor: 22.113

8.  Subnetwork-based analysis of chronic lymphocytic leukemia identifies pathways that associate with disease progression.

Authors:  Han-Yu Chuang; Laura Rassenti; Michelle Salcedo; Kate Licon; Alexander Kohlmann; Torsten Haferlach; Robin Foà; Trey Ideker; Thomas J Kipps
Journal:  Blood       Date:  2012-07-26       Impact factor: 22.113

9.  High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells.

Authors:  Sina Oppermann; Jarkko Ylanko; Yonghong Shi; Santosh Hariharan; Christopher C Oakes; Patrick M Brauer; Juan C Zúñiga-Pflücker; Brian Leber; David E Spaner; David W Andrews
Journal:  Blood       Date:  2016-06-13       Impact factor: 22.113

10.  IL-4 rescues surface IgM expression in chronic lymphocytic leukemia.

Authors:  Benchang Guo; Lu Zhang; Nicholas Chiorazzi; Thomas L Rothstein
Journal:  Blood       Date:  2016-05-25       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.